Amino Acid, Peptide, or Protein
Catalent’s Revival: Are the Dark Days Behind It Ahead of Novo Holdings Acquisition?
Catalent, Novo Holdings, acquisition, pharmaceutical industry, revenue boost, dark days, revival
Merck Halts Two Phase 3 Trials of Keytruda for Early-Stage Lung and Skin Cancers
Merck, Keytruda, Phase 3 trials, early-stage lung cancer, skin cancer, KEYNOTE-867, KEYNOTE-630
UCLA Receives $120 Million Donation for Immunology Research and Vaccine Development
UCLA, immunology research, vaccine development, $120 million donation, Gary Michelson, Alya Michelson, California Institute for Immunology and Immunotherapy
FDA Approves Illumina’s TruSight Oncology Comprehensive Test for Pan-Cancer Companion Diagnostics
FDA approval, Illumina, TruSight Oncology Comprehensive, pan-cancer, companion diagnostics, NTRK gene fusions, RET fusion-positive NSCLC, targeted therapies, precision oncology.
Neurocrine’s Schizophrenia Drug Shows Mixed Results in Phase 2 Trial
Neurocrine Biosciences, schizophrenia, NBI-1117568, KarXT, Bristol Myers Squibb, AbbVie, emraclidine, muscarinic receptors, antipsychotics
Navigator Medicines Launches with $100 Million Series A Funding to Advance Autoimmune Disease Bispecific Antibody
Navigator Medicines, autoimmune disease, bispecific antibody, Series A funding, RA Capital Management, Forbion
Roche’s PiaSky Receives European Approval for Rare Blood Disorder Treatment
Roche, PiaSky, Crovalimab, Paroxysmal Nocturnal Hemoglobinuria (PNH), Rare Blood Disorder, European Approval
Cigna’s Express Scripts to Remove Humira from Preferred Lists in Favor of Cheaper Biosimilars
Cigna, Express Scripts, Humira, biosimilars, drug pricing, pharmaceutical industry
Regeneron Secures EU Approval for Lymphoma Treatment Ordspono Following FDA Rejection
Regeneron, EU approval, lymphoma, bispecific antibody, odronextamab, Ordspono, FDA rejection
FDA Approves Updated Covid Vaccines for Fall Season: What You Need to Know
Covid-19 vaccines, FDA approval, updated vaccines, fall season, KP.2 strain, vaccination timing, immunity, side effects.